Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS)

Multiple Sclerosis, Primary Progressive Clinical Trial

Official title:

An Open-Label, Multicenter, Biomarker Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Patients With Relapsing Multiple Sclerosis or Primary Progressive Multiple Sclerosis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02688985
• Other study ID #: ML29966
• Secondary ID: 2015-004616-37
• Status: Completed
• Phase: Phase 3
• Start date: April 29, 2016
• Est. completion date: April 11, 2023

Study information

• Verified date: May 2024
• Source: Genentech, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open-label, multicenter, biomarker study designed to be hypothesis-generating in order to better understand the mechanism of action of ocrelizumab and B-cell biology in RMS or PPMS. The study will be conducted in two cohorts i.e. RMS cohort (4 arm group) and PPMS cohort (one arm group). RMS cohort: Ocrelizumab will be administered as two intravenous (IV) infusions of 300 milligrams (mg) on Days 1 and 15. Subsequent doses will be given as single 600-mg infusions at Weeks 24 and 48. Participants will be randomized in 1:1:1 ratio to receive lumbar puncture (LP) post-treatment at Week 12, 24, or 52 following the first dose of ocrelizumab in three arm groups. A fourth RMS arm with delayed treatment start (Arm 4 [control group]) will not be a part of the randomization and will be recruited separately, wherein treatment with ocrelizumab will be delayed for 12 weeks from pre-treatment baseline. PPMS cohort: Ocrelizumab 600 mg will be administered as two 300-mg IV infusions separated by 14 days at a scheduled interval of every 24 weeks. Participants will receive a LP at the start of the study before dosing with ocrelizumab and second LP at Week 52 following the first dose of ocrelizumab. A long-term extension will be conducted for participants that complete the study and continue to receive ocrelizumab. Treatment with ocrelizumab in the entire study will continue for approximately 4.5 years after the first infusion.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 131
• Est. completion date: April 11, 2023
• Est. primary completion date: April 11, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

General Inclusion Criteria:

• For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of <1 percent (%) per year during the treatment period and for at least 24 weeks after the last dose of study treatment or until their B-cells have repleted, whichever is longer

Inclusion Criteria Specific to RMS Participants:

• Diagnosis of RMS in accordance with the 2010 revised McDonald criteria

• Expanded Disability Status Scale (EDSS) score of 0 to 5.5 points, inclusive, at Screening

• Disease duration from the onset of multiple sclerosis symptoms less than (<) 15 years in participants with an EDSS score greater than (>) 5.0 at Screening

• Either treatment-naive or receiving treatment with disease-modifying therapies, including prior use of interferon (IFN)-beta-1a (Avonex®, Rebif®), IFN-beta-1b (Betaseron®/Betaferon), or glatiramer acetate (Copaxone®).

• At least one clinically documented relapse in the past year and/or at least one T1-weighted Gadolinium (Gd)-enhancing lesion in the past year and/or at least one new T2 lesion in the past year at the time of enrollment

Inclusion Criteria Specific to RMS Cohort Arm 4 Participants:

• Must meet inclusion criteria for the RMS cohort

• Separate signed Informed Consent Form for the RMS Delayed Time to Start Control Arm (Arm 4)

• Must be willing to remain on the same dose and regimen of current standard of care, or no treatment if treatment-naïve, for 12 weeks after study enrollment The treating and/or study physician must agree that the participant is eligible to remain on the same dose and regimen of their current standard of care at Screening, or to receive no treatment if the participant is treatment-naïve, for 12 weeks after study enrollment

Inclusion Criteria Specific to PPMS Participants:

• Diagnosis of PPMS in accordance with the 2010 revised McDonald criteria

• EDSS score of 3.0 - 6.5 points, inclusive, at Screening

• Disease duration from the onset of multiple sclerosis symptoms <10 years in participants with an EDSS at Screening less than or equal to (</=) 5.0

• Documented history of either elevated immunoglobulin G (IgG) Index or one or more IgG oligoclonal bands (OCBs) detected by isoelectric focusing

Exclusion Criteria:

• Diagnosis of secondary progressive multiple sclerosis without relapses for at least 1 year

• History or known presence of recurrent or chronic infection (e.g., human immunodeficiency virus [HIV], syphilis, tuberculosis)

• History of recurrent aspiration pneumonia requiring antibiotic therapy

• History of cancer, including solid tumors and hematological malignancies (except basal cell, in situ squamous cell carcinomas of the skin, and in situ carcinoma of the cervix of the uterus that have been excised and resolved with documented clean margins on pathology)

• History of or currently active primary or secondary immunodeficiency

• History of coagulation disorders

• History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies

• History of alcohol or other drug abuse within 24 weeks prior to enrollment

• Known presence or history of other neurologic disorders Significant, uncontrolled disease, such as cardiovascular (including cardiac arrhythmia), pulmonary (including chronic obstructive pulmonary disease), renal, hepatic, endocrine, gastrointestinal, or any other significant disease

• Congestive heart failure (according to New York Heart Association III or IV functional severity)

• Known active bacterial, viral, fungal, mycobacterial infection, or any major episode of infection requiring hospitalization or treatment with IV antibiotics

• Any concomitant disease that may require chronic treatment with systemic corticosteroids or immunosuppressants during the course of the study

• Contraindications or intolerance to oral or IV corticosteroids, including IV methylprednisolone, according to the country label

• Contraindication for LP

• Previous treatment with B cell-targeted therapies (such as rituximab, ocrelizumab, atacicept, belimumab, or ofatumumab)

• Previous treatment with natalizumab/Tysabri®, alemtuzumab, anti-CD4 agents, cladribine, teriflunomide, cyclophosphamide, mitoxantrone, azathioprine, mycophenolate mofetil, cyclosporine, methotrexate, total body irradiation, or bone marrow transplantation

• Treatment with fingolimod/Gilenya®, dimethyl fumarate/Tecfidera®, or similar treatment within 6 months prior to enrollment

• Receipt of a live vaccine within 6 weeks prior to enrollment

• Systemic corticosteroid therapy within 4 weeks prior to Baseline

• Previous or concurrent treatment with any investigational agent or treatment with any experimental procedure for multiple sclerosis (such as treatment for chronic cerebrospinal venous insufficiency)

• Certain laboratory abnormalities or findings at Screening

• Inability to complete an MRI

• Lack of peripheral venous access

• Pregnant or lactating, or intending to become pregnant during the study

Exclusion Criteria Specific to RMS Participants:

• Diagnosis of PPMS or secondary progressive multiple sclerosis without relapses

Related Conditions & MeSH terms

• Multiple Sclerosis
• Multiple Sclerosis, Chronic Progressive
• Multiple Sclerosis, Primary Progressive
• Relapsing Multiple Sclerorsis
• Sclerosis

Intervention

Drug:
• Ocrelizumab
Ocrelizumab will be administered as IV infusion.

Procedure:
• Lumbar Puncture
Participants will receive LP as specified in individual arms. Lumbar puncture is optional at week 52, except for RMS Cohort Arm 3 and PPMS Cohort. In addition, the lumbar punctures in the Long Term Extension phase is every other year.

Drug:
• Methyloprednisolone
Participants will receive 100 mg of IV methylprenisolone (or an equivalent) prior to ocrelizumab infusion.
• Antihistamine
Participants will receive an antihistamine, such as diphenhydramine, prior to ocrelizumab infusion.

Locations

Country	Name	City	State
Canada	McGill University; Montreal Neurological Institute; Neurological and Psychiatric	Montreal	Quebec
Canada	University of British Columbia Hospital Site; Djavad Mowafaghian Centre for Brain Health	Vancouver	British Columbia
Germany	Universitätsklinikum "Carl Gustav Carus" der Technischen Universität Dresden	Dresden
Germany	Universitätsmedizin Göttingen Georg-August-Universität	Göttingen
Sweden	Karolinska Universitetssjukhuset, Solna	Stockholm
United States	University Of Colorado	Aurora	Colorado
United States	University of North Carolina at Chapel Hill	Chapel Hill	North Carolina
United States	Ohio State University	Columbus	Ohio
United States	University of Texas Southwestern Medical Center	Dallas	Texas
United States	Empire Neurology, PC	Latham	New York
United States	Yale University School of Medicine ; Pulmonary & Critical Care	New Haven	Connecticut
United States	Weill Cornell MC-NY Presbyter; Dept. of Neurology/Neuroscience, Judith Jaffe Multiple Sclerosis Ctr	New York	New York
United States	Oklahoma Medical Research Foundation; MS Center of Excellence	Oklahoma City	Oklahoma
United States	Stanford University	Palo Alto	California
United States	Washington University; Wash Uni. Sch. Of Med	Saint Louis	Missouri
United States	University of California at San Francisco	San Francisco	California
United States	University of Massachusetts Medical School	Worcester	Massachusetts

Sponsors (1)

Lead Sponsor	Collaborator
Genentech, Inc.

Countries where clinical trial is conducted

United States,  Canada,  Germany,  Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Levels of NfL (Neurofilament Light) in CSF From Treatment Baseline to Post-Treatment With Ocrelizumab	Primary Analysis was based on following data-cut off: Arm 1: Baseline to post-treatment at 12 weeks Arm 2: Baseline to post-treatment at 24 weeks Arm 3: Baseline to post-treatment at 52 weeks Arm 4: Baseline to post-treatment at 12 weeks PPMS Cohort: Baseline to post-treatment at 52 weeks	From Baseline to post-treatment (Week 12, 24, 52 according to randomization and Weeks 144 and 240)
Primary	Change in Number of CD19+ B Cells in CSF From Treatment Baseline to Post-Treatment With Ocrelizumab	Arm 1: Baseline to post-treatment at 12 weeks Arm 2: Baseline to post-treatment at 24 weeks Arm 3: Baseline to post-treatment at 52 weeks Arm 4: Baseline to post-treatment at 12 weeks PPMS Cohort: Baseline to post-treatment at 52 weeks	From Baseline to post-treatment (Week 12, 24, 52 according to randomization and Weeks 144 and 240)
Primary	Change From Baseline in Number of CD3+ T-Cells in CSF Post-Treatment With Ocrelizumab	Arm 1: Baseline to post-treatment at 12 weeks Arm 2: Baseline to post-treatment at 24 weeks Arm 3: Baseline to post-treatment at 52 weeks Arm 4: Baseline to post-treatment at 12 weeks PPMS Cohort: Baseline to post-treatment at 52 weeks	From Baseline to post-treatment (Week 12, 24, 52 according to randomization and Weeks 144 and 240)